Assays for Anti-Helicobacter pylori Effects of Lactic Acid Bacteria Secretions.

Jean W Marbou Takougoum, Samantha A Whiteside, Daelyn G Carroll, Mahi M Mohiuddin, Stéphane Bronner, Sylvie Binda, Carole Creuzenet

Abstract read

PubMed Publisher

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jean W Marbou TakougoumMicrobiology and Immunology, The University of Western Ontario, London, ON, Canada.

Samantha A WhitesideMicrobiology and Immunology, The University of Western Ontario, London, ON, Canada.

Daelyn G CarrollMicrobiology and Immunology, The University of Western Ontario, London, ON, Canada.

Mahi M MohiuddinMicrobiology and Immunology, The University of Western Ontario, London, ON, Canada.

Stéphane BronnerLallemand Health Solutions, Rosell Institute for Microbiome and Probiotics, Montreal, Quebec, Canada.

Sylvie BindaLallemand Health Solutions, Rosell Institute for Microbiome and Probiotics, Montreal, Quebec, Canada.

Carole CreuzenetMicrobiology and Immunology, The University of Western Ontario, London, ON, Canada. ccreuzen@uwo.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori (HP) is a chronic bacterial pathogen that can cause gastric ulcers and cancers. The treatment for HP infections relies on a combination of antibiotics and proton pump inhibitors. Due to rising antibiotic resistance, curtailing HP-induced diseases requires identifying new anti-HP molecules that can reduce HP viability or impair its virulence, including its ability to cause inflammation. Oral intake of lactic acid bacteria (LAB) was shown to enhance the treatment of HP infection, and we demonstrated that LAB secretions can affect HP's growth and virulence factor production. This article describes a panel of in vitro assays that can be used to screen the anti-HP properties of multiple LAB secretions for the identification of novel anti-HP agents. The assays pertain to effects on viability, motility, urease production, and ability to elicit inflammation in gastric cells.

Indexed as

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriLactobacillalesHumansUreaseAnti-Bacterial AgentsUreaseCytokinesHelicobacter pyloriInflammationLactic acid bacteriaUrease

Identifiers

PMID40498307

DOI10.1128/JB.186.8.2253-2265.2004

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.